Abualhommos AK, Al Hawaj MA, Alshams HM et al (2026) Health-related quality of life and adherence to hydroxyurea in patients with sickle cell anemia in Saudi Arabia. Medicine 105:e46958. https://doi.org/10.1097/MD.0000000000046958

Article  PubMed  PubMed Central  Google Scholar 

Adeyemo TA, Diaku-Akinwunmi IN, Ojewunmi OO et al (2019) Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria. Hemoglobin 43:188–192. https://doi.org/10.1080/03630269.2019.1649278

Article  CAS  PubMed  Google Scholar 

Al-Zhrani FS, Ghoneim SH, Makin M et al (2020) Hydroxyurea adherence in adolescents and young adults with Sickle Cell Disease: An exploration of barriers to adherence in relation to health-related quality of life. 24

Alberts NM, Badawy SM, Hodges J et al (2020) Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. JMIR mHealth uHealth 8:e14884. https://doi.org/10.2196/14884

Article  PubMed  PubMed Central  Google Scholar 

Alherz IH, Al-Nass ZJ, Alkadi MA (2024) Utilization and Perceptions of Hydroxyurea Therapy Among Adult Patients With Sickle Cell Disease in Al Ahsa, Saudi Arabia: A Cross-Sectional Study. https://doi.org/10.7759/cureus.64666. Cureus

Ally M, Kakoko D, Omsland TK et al (2025) Level of Healthcare Facility and Psychosocial Factors Influence Perceived Self-Efficacy for Appropriate Use of Hydroxyurea: Experience from Caregivers of Children with Sickle Cell Disease in Tanzania. Healthcare 13. https://doi.org/10.3390/healthcare13131500

Badawy SM, Thompson AA, Lai J-S et al (2017) Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes 15:136. https://doi.org/10.1186/s12955-017-0713-x

Article  PubMed  PubMed Central  Google Scholar 

Brandow AM, Jirovec DL, Panepinto JA (2010) Hydroxyurea in Children with Sickle Cell Disease: Practice Patterns and Barriers to Utilization. Am J Hematol 85:611–613. https://doi.org/10.1002/ajh.21749

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campanaro CM, Livinalli A, Souza DL et al (2011) Evaluation of Treatment Adherence of Sickle Cell Pediatric patients in Use of hydroxyurea. Blood 118:4757. https://doi.org/10.1182/blood.V118.21.4757.4757

Article  Google Scholar 

Colombatti R, Birkegård C, Medici M (2022) PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW. https://doi.org/10.1097/01.HS9.0000851688.00394.f4. HemaSphere 6:2085

Dwuma-Badu D, Segbefia CI, Druye AA, Dei-Adomakoh YA (2022) Adherence to hydroxyurea therapy and health-related quality of life in children with sickle cell anaemia at Korle Bu Teaching Hospital in Ghana. Health Sci Investigations J 3:352–359

Google Scholar 

Fogarty H, Gaul A, Syed S et al (2022) Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease. Ir J Med Sci 191:809–816. https://doi.org/10.1007/s11845-021-02588-1

Article  PubMed  Google Scholar 

Galactéros F, Voskaridou E, Habibi A et al (2019) Sickle-Cell Disease Patients’ Attitudes Towards Their Treatment with Hydroxycarbamide. Blood 134:1013. https://doi.org/10.1182/blood-2019-125673

Article  Google Scholar 

Hong QN, Fàbregues S, Bartlett G et al (2018) The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Educ Inform 34:285–291. https://doi.org/10.3233/EFI-180221

Article  Google Scholar 

Isa HA, Nnebe-Agumadu U, Nwegbu MM et al (2022) Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria. PLoS ONE 17:e0276639. https://doi.org/10.1371/journal.pone.0276639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jose J, Elsadek RA, Jimmy B, George P (2019) Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman. Oman Med J 34:327–335. https://doi.org/10.5001/omj.2019.64

Article  PubMed  PubMed Central  Google Scholar 

Kilonzi M, Mlyuka HJ, Felician FF et al (2021) Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania. Hemato 2:713–726. https://doi.org/10.3390/hemato2040048

Article  PubMed  PubMed Central  Google Scholar 

Lebensburger JD, Sidonio RF, DeBaun MR et al (2013) Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatr Blood Cancer 60:1333–1337. https://doi.org/10.1002/pbc.24486

Article  PubMed  PubMed Central  Google Scholar 

Maria Inviolata Subira S, Ambrose EE, Konje E et al (2025) Adherence to Hydroxyurea Therapy for Pediatric Sickle Cell Anemia in Tanzania: Evidence from Bugando Medical Centre. Int J Environ Res Public Health 22. https://doi.org/10.3390/ijerph22040616

McArthur A, Cooper A, Edwards D et al (2025) Textual evidence systematic reviews series paper 3: critical appraisal of evidence from narrative, opinion, and policy. JBI Evid Synthesis 23:833–839. https://doi.org/10.11124/JBIES-24-00293

Article  Google Scholar 

Meena P, Pathak S, Lazarus M, Kumari V (2025) Short stature in children with homozygous sickle cell disease: Clinical correlates and risk factors from a single-centre cohort in central India. Pediatr Hematol Oncol J 10:100778. https://doi.org/10.1016/j.phoj.2025.100778

Article  Google Scholar 

Mensah J, Asare Marfo AF, Opare-Addo MNA et al (2026) Assessing hydroxyurea use in sickle cell disease: trends, benefits, and barriers to adherence in a Ghanaian tertiary hospital. J Sickle Cell Dis 3:yoag001. https://doi.org/10.1093/jscdis/yoag001

Article  Google Scholar 

Mlyuka HJ, Kilonzi M, Mutagonda RF et al (2022) Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators. https://doi.org/10.3390/healthcare10112223. Healthcare 10:

Namaganda P, Nantume P, Mubiru KR et al (2024) Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study. BMC Health Serv Res 24:666. https://doi.org/10.1186/s12913-024-11125-6

Article  PubMed  PubMed Central  Google Scholar 

Nirmal G, Pendharkar D, Gupta N, Raj A (2025) Knowledge, Attitude, and Practice of Patients Suffering From Sickle Cell Disease in an Endemic Zone. J Pediatr Hematol Oncol 47:86. https://doi.org/10.1097/MPH.0000000000002987

Article  CAS  PubMed  Google Scholar 

Ofakunrin AO, Okpe ES, Afolaranmi TO et al (2021) Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria. Afr Health Sci 21:765–774. https://doi.org/10.4314/ahs.v21i2.36

Article  PubMed  PubMed Central  Google Scholar 

Okocha EC, Gyamfi J, Ryan N et al (2022) Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey. Front Genet 12. https://doi.org/10.3389/fgene.2021.765958

Prajapati GK, Sharma S, Shrivastava J (2022) Effect of Counselling on Compliance of Hydroxyurea Therapy and Frequency of Hospital Admissions among Patients with Sickle Cell Disease- A Longitudinal Study. https://doi.org/10.7860/JCDR/2022/57120.16922. JCDR

Raman V, Seshadri T, Joice SV, Srinivas PN (2021) Sickle cell disease in India: a scoping review from a health systems perspective to identify an agenda for research and action. BMJ Glob Health 6. https://doi.org/10.1136/bmjgh-2020-004322

Smaldone A, Manwani D, Aygun B et al (2024) Assessing multilevel barriers to hydroxyurea adherence in youth with sickle cell disease using pharmacy-based refill records. Pediatr Blood Cancer 71:e31170. https://doi.org/10.1002/pbc.31170

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith AW, Bodas P, Sidebotham L et al (2019) Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices. J Natl Med Assoc 111:169–175. https://doi.org/10.1016/j.jnma.2018.09.004

Article  PubMed  Google Scholar 

Thomson AM, McHugh TA, Oron AP et al (2023) Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol 10:e585–e599. https://doi.org/10.1016/S2352-3026(23)00118-7

Article  Google Scholar 

Treadwell MJ, Du L, Bhasin N et al (2022) Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative. Front Genet 13. https://doi.org/10.3389/fgene.2022.921432

Venugopalan VM, Banerjee A, Rajamani N et al (2025) Exploring barriers and strategies for hydroxyurea uptake using the CFIR–ERIC framework: A qualitative study of sickle cell disease in India. Clin Epidemiol Global Health. https://doi.org/10.1016/j.cegh.2025.102205. 36:

Article  Google Scholar 

Wang WC, Ware RE, Miller ST et al (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377:1663–1672. https://doi.org/10.1016/S0140-6736(11)60355-3

Article  CAS  PubMed  PubMed Central  Google Scholar